MAP2K7 and cancer: Our study highlights the substantial unmet clinical need of Class II and Class III BRAF-mutations in lung cancer and provides a new biomarker-driven therapeutic opportunity, exarafenib and/or combination exarafenib plus MEK inhibitor treatment, to address this prevalent and aggressive cancer subtype.